Zynerba shares surge after Main Line firm wins patent for its CBD gel to treat Autism Spectrum Disorders
Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals Gives A Clinical Update And Lifelong Impact Of ZYN002
Zynerba Discontinues Development Of Cannabidiol Gel In Epileptic Disorders
Zynerba Pharmaceuticals Inc: Zynerba delays genetic disorder drug data on enrollment challenge, ET HealthWorld
News snapshot: Irwin Naturals, Fireweed Zinc, CULT Food Science, Zynerba Pharmaceuticals, Bridgeline Digital...
Zynerba's CBD Drug Shows Promise for Fragile X Syndrome · BioBuzz
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Will Zynerba Pharmaceuticals Inc (ZYNE) Stay at the Bottom of the Healthcare Sector?
Zynerba Pharmaceuticals Presents During NFXF's 2022 Industry Updates | NFXF
Zynerba Pharmaceuticals, Inc. (ZYNE) Stock Price Today, Quote & News | Seeking Alpha
Zynerba Pharma (@ZynerbaPharma) / Twitter
Why Zynerba Pharmaceuticals Stock Is Crashing Today | The Motley Fool
Zynerba Pharmaceuticals | LinkedIn
Do Traders Think Zynerba Pharmaceuticals Inc (ZYNE) Can Turn Around Tuesday?
Zynerba Pharma (@ZynerbaPharma) / Twitter
Zynerba Pharmaceuticals Inc Shares Approach 52-Week Low - Market Mover | Nasdaq
Zynerba's Stock Forecast for 2021: Is ZYNE a Good Stock to Buy?
Stocks to Watch: General Mills, Zynerba Pharmaceuticals, FedEx, Chewy and More - WSJ
ZYNE Stock Price and Chart — NASDAQ:ZYNE — TradingView
Zynerba Pharma News, Zynerba Pharma Quote, ZYNE Quote - StreetInsider.com
